LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Home・Lista de Ações・ResMed Inc

ResMed Inc

Fechado

SetorSaúde

203.88 2.85

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

198.81

Máximo

204.91

Indicadores-chave
By Trading Economics
Rendimento	6.1M 399M
Vendas	8.6M 1.4B
P/E Médio do Setor	19.758 49.8
EPS	2.86
Rendimento de Dividendos	1.14
Margem de lucro	27.856
Funcionários	10,600
EBITDA	-67M 500M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+33.11% upside

Dividendos
By Dow Jones
Rendimento de Dividendos Médio do Setor	1.14% 2.25%
Próximos Ganhos	30 de jul. de 2026
Próxima data de dividendos	18 de jun. de 2026
Próxima data de ex-dividendo	14 de mai. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-2B 30B
Abertura anterior	201.03
Fecho anterior	203.88

Sentimento de Notícias

By Acuity

88%

12%

331 / 346 Ranking em Healthcare

ResMed Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

12 de mai. de 2026, 22:50 UTC

Ganhos

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 de mai. de 2026, 22:49 UTC

Ganhos

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 de mai. de 2026, 22:32 UTC

Ganhos

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 de mai. de 2026, 23:48 UTC

Conversa de Mercado

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 de mai. de 2026, 22:57 UTC

Conversa de Mercado

Ganhos

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 de mai. de 2026, 22:26 UTC

Ganhos

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 de mai. de 2026, 22:25 UTC

Ganhos

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 de mai. de 2026, 22:25 UTC

Ganhos

Aristocrat Leisure Interim Dividend A$0.50/Security

12 de mai. de 2026, 22:24 UTC

Ganhos

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 de mai. de 2026, 22:23 UTC

Ganhos

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 de mai. de 2026, 22:23 UTC

Ganhos

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 de mai. de 2026, 22:19 UTC

Ganhos

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 de mai. de 2026, 22:14 UTC

Ganhos

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 de mai. de 2026, 22:14 UTC

Ganhos

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 de mai. de 2026, 22:13 UTC

Ganhos

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 de mai. de 2026, 22:12 UTC

Ganhos

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 de mai. de 2026, 22:12 UTC

Ganhos

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 de mai. de 2026, 22:11 UTC

Ganhos

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 de mai. de 2026, 22:11 UTC

Ganhos

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 de mai. de 2026, 22:10 UTC

Ganhos

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 de mai. de 2026, 22:09 UTC

Ganhos

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 de mai. de 2026, 22:09 UTC

Ganhos

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 de mai. de 2026, 22:08 UTC

Ganhos

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 de mai. de 2026, 22:07 UTC

Ganhos

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 de mai. de 2026, 22:06 UTC

Ganhos

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 de mai. de 2026, 22:06 UTC

Ganhos

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 de mai. de 2026, 22:05 UTC

Ganhos

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 de mai. de 2026, 22:04 UTC

Ganhos

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 de mai. de 2026, 22:04 UTC

Ganhos

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 de mai. de 2026, 22:04 UTC

Ganhos

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Comparação entre Pares

Variação de preço

ResMed Inc Previsão

Preço-alvo

By TipRanks

33.11% parte superior

Previsão para 12 meses

Média 264.56 USD 33.11%

Máximo 340 USD

Mínimo 225 USD

Com base em 13 analistas de Wall Street que oferecem metas de preço de 12 meses para ResMed Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

13 ratings

Comprar

Manter

Vender

Com base em 13 analistas que deram avaliações de ações para ResMed Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

331 / 346 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre ResMed Inc

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.